{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:08:02Z","timestamp":1787069282073,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the medical and health research project of Zhejiang province","award":["2025KY1088"],"award-info":[{"award-number":["2025KY1088"]}]},{"name":"the medical and health research project of Zhejiang province","award":["2025KY1085"],"award-info":[{"award-number":["2025KY1085"]}]},{"name":"the medical and health research project of Zhejiang province","award":["2024KY1312"],"award-info":[{"award-number":["2024KY1312"]}]},{"name":"the basic public welfare research project of Zhejiang province","award":["LGF22H070008"],"award-info":[{"award-number":["LGF22H070008"]}]},{"DOI":"10.13039\/501100001809","name":"National natural science foundation of China","doi-asserted-by":"crossref","award":["82300254"],"award-info":[{"award-number":["82300254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01400-5","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:09:38Z","timestamp":1782115778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review"],"prefix":"10.1007","volume":"27","author":[{"given":"Juncong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-4202","authenticated-orcid":false,"given":"Dingcun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"5","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1089\/thy.2016.0395","volume":"27","author":"SN Rao","year":"2017","unstructured":"Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid. 2017;27(5):672\u201381. https:\/\/doi.org\/10.1089\/thy.2016.0395.","journal-title":"Thyroid"},{"issue":"9","key":"1400_CR2","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J translational Res. 2019;11(9):5888\u201396.","journal-title":"Am J translational Res"},{"issue":"12","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1089\/thy.2021.0307","volume":"31","author":"NS Huang","year":"2021","unstructured":"Huang NS, Wei WJ, Xiang J, Chen JY, Guan Q, Lu ZW, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial. Thyroid\u00ae. 2021;31(12):1808\u201313. https:\/\/doi.org\/10.1089\/thy.2021.0307.","journal-title":"Thyroid\u00ae"},{"issue":"8","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid\u00ae. 2019;29(8):1036\u201343. https:\/\/doi.org\/10.1089\/thy.2019.0133.","journal-title":"Thyroid\u00ae"},{"issue":"3","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1002\/cam4.5219","volume":"12","author":"H Yamazaki","year":"2023","unstructured":"Yamazaki H, Sugino K, Katoh R, Matsuzu K, Masaki C, Akaishi J, et al. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. Cancer Med. 2023;12(3):3027\u201335. https:\/\/doi.org\/10.1002\/cam4.5219.","journal-title":"Cancer Med"},{"issue":"1","key":"1400_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12020-023-03556-8","volume":"84","author":"O Abdel-Rahman","year":"2024","unstructured":"Abdel-Rahman O, Ghosh S. Changes in the outcomes of patients with anaplastic thyroid carcinoma over the past two decades. Endocrine. 2024;84(1):155\u20139. https:\/\/doi.org\/10.1007\/s12020-023-03556-8.","journal-title":"Endocrine"},{"issue":"2","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2024;20(2):93\u2013110. https:\/\/doi.org\/10.1038\/s41574-023-00920-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid\u00ae. 2020;30(10):1505\u201317. https:\/\/doi.org\/10.1089\/thy.2020.0086.","journal-title":"Thyroid\u00ae"},{"issue":"3","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/erc-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143-55. https:\/\/doi.org\/10.1530\/erc-15-0533.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1400_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29(5):946\u201360. https:\/\/doi.org\/10.1038\/s41418-022-00988-z.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399. https:\/\/doi.org\/10.1038\/nrc3431.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1400_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"1400_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011226","author":"R Seger","year":"2024","unstructured":"Seger R. Special issue: MAPK signaling cascades in human health and diseases. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252011226.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385. https:\/\/doi.org\/10.1038\/nrm1498.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1400_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03033-1","volume":"9","author":"R Liu","year":"2018","unstructured":"Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nat Commun. 2018;9(1):579. https:\/\/doi.org\/10.1038\/s41467-018-03033-1.","journal-title":"Nat Commun"},{"issue":"8","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550\u201362. https:\/\/doi.org\/10.1038\/nrc2664.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1400_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/thy.2010.1646","volume":"20","author":"M Xing","year":"2010","unstructured":"Xing M. Genetic alterations in the phosphatidylinositol-3 kinase\/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697\u2013706. https:\/\/doi.org\/10.1089\/thy.2010.1646.","journal-title":"Thyroid"},{"issue":"11","key":"1400_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","volume":"13","author":"E Molinaro","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644\u201360. https:\/\/doi.org\/10.1038\/nrendo.2017.76.","journal-title":"Nat Rev Endocrinol"},{"issue":"18","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.Can-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3962.","journal-title":"Cancer Res"},{"issue":"16","key":"1400_CR20","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.7150\/jca.44506","volume":"11","author":"H Yin","year":"2020","unstructured":"Yin H, Tang Y, Guo Y, Wen S. Immune microenvironment of thyroid cancer. J Cancer. 2020;11(16):4884\u201396. https:\/\/doi.org\/10.7150\/jca.44506.","journal-title":"J Cancer"},{"key":"1400_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12249","author":"J Lv","year":"2021","unstructured":"Lv J, Liu C, Chen FK, Feng ZP, Jia L, Liu PJ, et al. M2\u2011like tumour\u2011associated macrophage\u2011secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K\/AKT\/mTOR pathway. Mol Med Rep. 2021. https:\/\/doi.org\/10.3892\/mmr.2021.12249.","journal-title":"Mol Med Rep"},{"issue":"7","key":"1400_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022567","volume":"6","author":"B Caillou","year":"2011","unstructured":"Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011;6(7):e22567. https:\/\/doi.org\/10.1371\/journal.pone.0022567.","journal-title":"PLoS One"},{"key":"1400_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01999","volume":"10","author":"J Bi","year":"2019","unstructured":"Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol. 2019;10:1999. https:\/\/doi.org\/10.3389\/fimmu.2019.01999.","journal-title":"Front Immunol"},{"issue":"1","key":"1400_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58910-3","volume":"16","author":"Z Pan","year":"2025","unstructured":"Pan Z, Tan Z, Xu N, Yao Z, Zheng C, Shang J, et al. Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers. Nat Commun. 2025;16(1):3601. https:\/\/doi.org\/10.1038\/s41467-025-58910-3.","journal-title":"Nat Commun"},{"issue":"5","key":"1400_CR25","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4049\/jimmunol.1900543","volume":"204","author":"L Cristinziano","year":"1950","unstructured":"Cristinziano L, Modestino L, Loffredo S, Varricchi G, Braile M, Ferrara AL, et al. Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol. 1950;204(5):1362\u201372. https:\/\/doi.org\/10.4049\/jimmunol.1900543.","journal-title":"J Immunol"},{"issue":"4","key":"1400_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3892\/mco.2013.170","volume":"1","author":"S Suzuki","year":"2013","unstructured":"Suzuki S, Shibata M, Gonda K, Kanke Y, Ashizawa M, Ujiie D, et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol. 2013;1(6):959\u201364. https:\/\/doi.org\/10.3892\/mco.2013.170.","journal-title":"Mol Clin Oncol"},{"issue":"1b","key":"1400_CR28","first-page":"761","volume":"19","author":"H Asakawa","year":"1999","unstructured":"Asakawa H, Kobayashi T. The secretion of cytokines and granulocyte colony stimulating factor by anaplastic and poorly differentiated thyroid carcinoma cell lines. Anticancer Res. 1999;19(1b):761\u20134.","journal-title":"Anticancer Res"},{"issue":"1","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.Cir-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0297.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"1400_CR30","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.Ccr-17-0691","volume":"24","author":"A Stiff","year":"2018","unstructured":"Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor-mediated natural killer cell function. Clin Cancer Res. 2018;24(8):1891\u2013904. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0691.","journal-title":"Clin Cancer Res"},{"key":"1400_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226443","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang J, Zhao Y, Zhao K, Yin K, Wang S. Function of reactive oxygen species in myeloid-derived suppressor cells. Front Immunol. 2023;14:1226443. https:\/\/doi.org\/10.3389\/fimmu.2023.1226443.","journal-title":"Front Immunol"},{"issue":"7","key":"1400_CR32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.ymthe.2023.05.007","volume":"31","author":"C Wang","year":"2023","unstructured":"Wang C, Yuan X, Xue J. Targeted therapy for rare lung cancers: status, challenges, and prospects. Mol Ther. 2023;31(7):1960\u201378. https:\/\/doi.org\/10.1016\/j.ymthe.2023.05.007.","journal-title":"Mol Ther"},{"issue":"3","key":"1400_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629\u201352. https:\/\/doi.org\/10.1007\/s10555-023-10084-4.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1400_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105. https:\/\/doi.org\/10.1186\/s12943-023-01805-y.","journal-title":"Mol Cancer"},{"key":"1400_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","volume":"135","author":"R Roskoski Jr","year":"2018","unstructured":"Roskoski R Jr. Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers. Pharmacol Res. 2018;135:239\u201358. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.013.","journal-title":"Pharmacol Res"},{"issue":"11","key":"1400_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","volume":"73","author":"CJ Wright","year":"2013","unstructured":"Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013;73(11):1245\u201354. https:\/\/doi.org\/10.1007\/s40265-013-0096-1.","journal-title":"Drugs"},{"key":"1400_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","volume":"117","author":"R Roskoski Jr","year":"2017","unstructured":"Roskoski R Jr. Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacol Res. 2017;117:20\u201331. https:\/\/doi.org\/10.1016\/j.phrs.2016.12.009.","journal-title":"Pharmacol Res"},{"issue":"8","key":"1400_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1502309.","journal-title":"N Engl J Med"},{"issue":"1","key":"1400_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jco.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7\u201313. https:\/\/doi.org\/10.1200\/jco.2017.73.6785.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1400_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014.","journal-title":"Ann Oncol"},{"issue":"11","key":"1400_CR41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40265-025-02233-6","volume":"85","author":"L Cheng","year":"2025","unstructured":"Cheng L, Newbold K. Systemic therapy for advanced thyroid cancer-new personalized options. Drugs. 2025;85(11):1381\u201390. https:\/\/doi.org\/10.1007\/s40265-025-02233-6.","journal-title":"Drugs"},{"issue":"4","key":"1400_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-04729-4","volume":"80","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, et al. Receptor tyrosine kinase inhibitors in cancer. Cell Mol Life Sci. 2023;80(4):104. https:\/\/doi.org\/10.1007\/s00018-023-04729-4.","journal-title":"Cell Mol Life Sci"},{"key":"1400_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2026.108107","volume":"224","author":"R Roskoski Jr","year":"2026","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacol Res. 2026;224:108107. https:\/\/doi.org\/10.1016\/j.phrs.2026.108107.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1400_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1089\/thy.2010.0057","volume":"20","author":"HT Ha","year":"2010","unstructured":"Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975\u201380. https:\/\/doi.org\/10.1089\/thy.2010.0057.","journal-title":"Thyroid"},{"issue":"2","key":"1400_CR45","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8\u2009+\u2009T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14(2):e0212513. https:\/\/doi.org\/10.1371\/journal.pone.0212513.","journal-title":"PLoS ONE"},{"key":"1400_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25. https:\/\/doi.org\/10.3389\/fonc.2017.00025.","journal-title":"Front Oncol"},{"issue":"21","key":"1400_CR47","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/jco.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021;39(21):2359\u201366. https:\/\/doi.org\/10.1200\/jco.20.03093.","journal-title":"J Clin Oncol"},{"issue":"10061","key":"1400_CR48","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/s0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet (London England). 2016;388(10061):2783\u201395. https:\/\/doi.org\/10.1016\/s0140-6736(16)30172-6.","journal-title":"Lancet (London England)"},{"issue":"7","key":"1400_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1406470.","journal-title":"N Engl J Med"},{"key":"1400_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051040","author":"F Cuomo","year":"2022","unstructured":"Cuomo F, Giani C, Cobellis G. The role of the kinase inhibitors in thyroid cancers. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14051040.","journal-title":"Pharmaceutics"},{"key":"1400_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010010","author":"OV Ancker","year":"2019","unstructured":"Ancker OV, Kr\u00fcger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms21010010.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1400_CR52","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40265-024-02040-5","volume":"84","author":"MF Chen","year":"2024","unstructured":"Chen MF, Repetto M, Wilhelm C, Drilon A. RET inhibitors in RET fusion-positive lung cancers: past, present, and future. Drugs. 2024;84(9):1035\u201353. https:\/\/doi.org\/10.1007\/s40265-024-02040-5.","journal-title":"Drugs"},{"issue":"8","key":"1400_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1714448.","journal-title":"N Engl J Med"},{"issue":"12","key":"1400_CR54","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1400_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/s1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21(4):531\u201340. https:\/\/doi.org\/10.1016\/s1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1400_CR56","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/eje-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631\u201343. https:\/\/doi.org\/10.1530\/eje-21-1259.","journal-title":"Eur J Endocrinol"},{"issue":"23","key":"1400_CR57","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/jco.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620\u20137. https:\/\/doi.org\/10.1200\/jco.19.02727.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1400_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr., et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337\u201386. https:\/\/doi.org\/10.1089\/thy.2020.0944.","journal-title":"Thyroid"},{"issue":"2","key":"1400_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017.","journal-title":"Cell"},{"issue":"7","key":"1400_CR60","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.Ccr-17-2297","volume":"24","author":"GJ Hanna","year":"2018","unstructured":"Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res. 2018;24(7):1546\u201353. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2297.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1400_CR61","first-page":"6105","volume":"61","author":"MD Ringel","year":"2001","unstructured":"Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61(16):6105\u201311.","journal-title":"Cancer Res"},{"issue":"4","key":"1400_CR62","doi-asserted-by":"publisher","first-page":"E577","DOI":"10.1210\/jc.2010-2644","volume":"96","author":"R Liu","year":"2011","unstructured":"Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K\/Akt pathway. J Clin Endocrinol Metab. 2011;96(4):E577-85. https:\/\/doi.org\/10.1210\/jc.2010-2644.","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"1400_CR63","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"issue":"20","key":"1400_CR64","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"5","key":"1400_CR65","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370. https:\/\/doi.org\/10.1038\/s41590-022-01141-1.","journal-title":"Nat Immunol"},{"issue":"1","key":"1400_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4.","journal-title":"Mol Cancer"},{"issue":"4","key":"1400_CR67","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","volume":"35","author":"M Boruah","year":"2024","unstructured":"Boruah M, Agarwal S, Mir RA, Choudhury SD, Sikka K, Rastogi S, et al. Unravelling the reasons behind limited response to anti-PD therapy in ATC: a comprehensive evaluation of tumor-infiltrating immune cells and checkpoints. Endocr Pathol. 2024;35(4):419\u201331. https:\/\/doi.org\/10.1007\/s12022-024-09832-1.","journal-title":"Endocr Pathol"},{"key":"1400_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061304","author":"B Chern","year":"2024","unstructured":"Chern B, Pinto D, Lum JH, Parameswaran R. Nearly half of patients with anaplastic thyroid cancer may be amenable to immunotherapy. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12061304.","journal-title":"Biomedicines"},{"issue":"10","key":"1400_CR69","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/pas.0000000000002284","volume":"48","author":"S Agarwal","year":"2024","unstructured":"Agarwal S, Jung CK, Gaddam P, Hirokawa M, Higashiyama T, Hang JF, et al. PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma. Am J Surg Pathol. 2024;48(10):1233\u201344. https:\/\/doi.org\/10.1097\/pas.0000000000002284.","journal-title":"Am J Surg Pathol"},{"issue":"6382","key":"1400_CR70","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci (New York NY). 2018;359(6382):1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Sci (New York NY)"},{"issue":"7","key":"1400_CR71","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076\u201385. https:\/\/doi.org\/10.1089\/thy.2020.0322.","journal-title":"Thyroid"},{"issue":"1","key":"1400_CR72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68. https:\/\/doi.org\/10.1186\/s40425-018-0378-y.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"1400_CR73","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1158\/1078-0432.Ccr-17-2008","volume":"23","author":"IM Min","year":"2017","unstructured":"Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin Cancer Res. 2017;23(24):7569\u201383. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2008.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1400_CR74","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1158\/1078-0432.Ccr-20-1523","volume":"26","author":"KD Gray","year":"2020","unstructured":"Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, et al. PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer. Clin Cancer Res. 2020;26(22):6003\u201316. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1523.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1400_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1400_CR76","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360. https:\/\/doi.org\/10.7150\/ijbs.34213.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"1400_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.eprac.2024.11.012","volume":"31","author":"P Song","year":"2025","unstructured":"Song P, Pan G, Zhang Y, Ni Y, Wang Q, Shi J, et al. Prospects and challenges of immunotherapy for thyroid cancer. Endocr Pract. 2025;31(3):373\u20139. https:\/\/doi.org\/10.1016\/j.eprac.2024.11.012.","journal-title":"Endocr Pract"},{"issue":"11","key":"1400_CR78","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704. https:\/\/doi.org\/10.1038\/s41587-023-02060-8.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1400_CR79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1400_CR80","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/jc.2012-1520","volume":"97","author":"KC Bible","year":"2012","unstructured":"Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):3179\u201384. https:\/\/doi.org\/10.1210\/jc.2012-1520.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1400_CR81","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/thy.2012.0103","volume":"23","author":"P Savvides","year":"2013","unstructured":"Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600\u20134. https:\/\/doi.org\/10.1089\/thy.2012.0103.","journal-title":"Thyroid"},{"issue":"1","key":"1400_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01555-y","volume":"24","author":"D Soll","year":"2024","unstructured":"Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, et al. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord. 2024;24(1):25. https:\/\/doi.org\/10.1186\/s12902-024-01555-y.","journal-title":"BMC Endocr Disord"},{"key":"1400_CR83","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4019","author":"K Sehgal","year":"2024","unstructured":"Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, et al. <article-title update=\"added\">Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma. JAMA Oncol. 2024. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4019.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1400_CR84","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, et al. Anti-Programmed Death Ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial. JAMA Oncol. 2024;10(12):1672\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4729.","journal-title":"JAMA Oncol"},{"key":"1400_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104463","volume":"202","author":"LP Ciccone","year":"2024","unstructured":"Ciccone LP, Franzetti J, Bonora M, Ronchi S, Camarda AM, Charalampopoulou A, et al. Charged particle radiotherapy for thyroid cancer. A systematic review. Crit Rev Oncol Hematol. 2024;202:104463. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104463.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1400_CR86","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(10)70290-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1400_CR87","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrclinonc.2009.183","volume":"7","author":"M Durante","year":"2010","unstructured":"Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7(1):37\u201343. https:\/\/doi.org\/10.1038\/nrclinonc.2009.183.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1400_CR88","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/hed.27877","volume":"46","author":"SS Vasudevan","year":"2024","unstructured":"Vasudevan SS, Deeb H, Katta A, Olinde L, Pang J, Asarkar AA, et al. Efficacy and safety of proton therapy versus intensity-modulated radiation therapy in the treatment of head and neck tumors: a systematic review and meta-analysis. Head Neck. 2024;46(10):2616\u201331. https:\/\/doi.org\/10.1002\/hed.27877.","journal-title":"Head Neck"},{"issue":"2","key":"1400_CR89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14338\/ijpt-22-00005.1","volume":"9","author":"I Youssef","year":"2022","unstructured":"Youssef I, Yoon J, Mohamed N, Zakeri K, Press RH, Yu Y, et al. Outcomes and toxicities of nonmedullary thyroid tumors treated with proton beam radiation therapy. Int J Part Ther. 2022;9(2):20\u201330. https:\/\/doi.org\/10.14338\/ijpt-22-00005.1.","journal-title":"Int J Part Ther"},{"issue":"1","key":"1400_CR90","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijrobp.2025.09.050","volume":"124","author":"A Beddok","year":"2026","unstructured":"Beddok A, Morvan JB, Boudin L, Da Silva Ribeiro Mota A, Dutheil P, Guilbert P, et al. The role of external beam radiation therapy in thyroid cancer management: a scoping review. Int J Radiat Oncol Biol Phys. 2026;124(1):70\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1400_CR91","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/jjco\/hyr095","volume":"41","author":"K Tanaka","year":"2011","unstructured":"Tanaka K, Sugitani I, Fujimoto Y. A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol. 2011;41(9):1074\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyr095.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1400_CR92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/thy.2009.0115","volume":"20","author":"T Higashiyama","year":"2010","unstructured":"Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20(1):7\u201314. https:\/\/doi.org\/10.1089\/thy.2009.0115.","journal-title":"Thyroid"},{"issue":"9","key":"1400_CR93","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1089\/thy.2016.0072","volume":"26","author":"N Onoda","year":"2016","unstructured":"Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K, et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid. 2016;26(9):1293\u20139. https:\/\/doi.org\/10.1089\/thy.2016.0072.","journal-title":"Thyroid"},{"issue":"1","key":"1400_CR94","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","volume":"17","author":"S Saini","year":"2018","unstructured":"Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):154. https:\/\/doi.org\/10.1186\/s12943-018-0903-0.","journal-title":"Mol Cancer"},{"issue":"12","key":"1400_CR95","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","volume":"102","author":"N Prasongsook","year":"2017","unstructured":"Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2017;102(12):4506\u201314. https:\/\/doi.org\/10.1210\/jc.2017-01180.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1400_CR96","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, et al. Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid. 2024;34(3):336\u201346. https:\/\/doi.org\/10.1089\/thy.2023.0573.","journal-title":"Thyroid"},{"key":"1400_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040862","author":"K Enomoto","year":"2021","unstructured":"Enomoto K, Hirayama S, Kumashiro N, Jing X, Kimura T, Tamagawa S, et al. Synergistic effects of Lenvatinib (E7080) and MEK inhibitors against anaplastic thyroid cancer in preclinical models. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040862.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1400_CR98","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1089\/thy.2023.0201","volume":"33","author":"V Gunda","year":"2023","unstructured":"Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, et al. Combination BRAF(V600E) inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAF(V600E)-mutant anaplastic thyroid cancer. Thyroid. 2023;33(10):1201\u201314. https:\/\/doi.org\/10.1089\/thy.2023.0201.","journal-title":"Thyroid"},{"issue":"13","key":"1400_CR99","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270. https:\/\/doi.org\/10.1056\/NEJMc1509660.","journal-title":"N Engl J Med"},{"issue":"12","key":"1400_CR100","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993\u20134002. https:\/\/doi.org\/10.1111\/cas.13806.","journal-title":"Cancer Sci"},{"issue":"9","key":"1400_CR101","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/ijc.32041","volume":"144","author":"V Gunda","year":"2019","unstructured":"Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, et al. Anti-PD-1\/PD-L1 therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer. 2019;144(9):2266\u201378. https:\/\/doi.org\/10.1002\/ijc.32041.","journal-title":"Int J Cancer"},{"key":"1400_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1389294","volume":"15","author":"D Barbaro","year":"2024","unstructured":"Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, et al. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report. Front Endocrinol. 2024;15:1389294. https:\/\/doi.org\/10.3389\/fendo.2024.1389294.","journal-title":"Front Endocrinol"},{"issue":"10","key":"1400_CR103","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","volume":"119","author":"V Gunda","year":"2018","unstructured":"Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, et al. Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018;119(10):1223\u201332. https:\/\/doi.org\/10.1038\/s41416-018-0296-2.","journal-title":"Br J Cancer"},{"key":"1400_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","volume":"13","author":"S Zhu","year":"2022","unstructured":"Zhu S, Wang Y, Tang J, Cao M. Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Front Immunol. 2022;13:1074477. https:\/\/doi.org\/10.3389\/fimmu.2022.1074477.","journal-title":"Front Immunol"},{"issue":"5","key":"1400_CR105","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.aace.2021.03.003","volume":"7","author":"SR Yang","year":"2021","unstructured":"Yang SR, Tsai MH, Hung CJ, Peng SL, Chiu NT, Huang YH, et al. Anaplastic thyroid cancer successfully treated with radiation and immunotherapy: a case report. AACE Clin Case Rep. 2021;7(5):299\u2013302. https:\/\/doi.org\/10.1016\/j.aace.2021.03.003.","journal-title":"AACE Clin Case Rep"},{"issue":"11","key":"1400_CR106","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1089\/thy.2019.0086","volume":"29","author":"AV Chintakuntlawar","year":"2019","unstructured":"Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, et al. A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid\u00ae. 2019;29(11):1615\u201322. https:\/\/doi.org\/10.1089\/thy.2019.0086.","journal-title":"Thyroid\u00ae"},{"issue":"1","key":"1400_CR107","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.2017.145","volume":"117","author":"GJ Weiss","year":"2017","unstructured":"Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017;117(1):33\u201340. https:\/\/doi.org\/10.1038\/bjc.2017.145.","journal-title":"Br J Cancer"},{"issue":"7","key":"1400_CR108","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.008.","journal-title":"Ann Oncol"},{"issue":"3","key":"1400_CR109","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12020-023-03647-6","volume":"84","author":"G Wu","year":"2024","unstructured":"Wu G, Song Y, Yang S, Li H, Liu S, Gui L, et al. The role of targeted therapy and\/or immunotherapy therapy in anaplastic thyroid carcinoma. Endocrine. 2024;84(3):1013\u201320. https:\/\/doi.org\/10.1007\/s12020-023-03647-6.","journal-title":"Endocrine"},{"issue":"32","key":"1400_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000026138","volume":"100","author":"L Zheng","year":"2021","unstructured":"Zheng L, Li L, He Q, Wang M, Ma Y, Zhu J, et al. Response to immunotherapy in a patient with anaplastic thyroid cancer: a case report. Medicine (Baltimore). 2021;100(32):e26138. https:\/\/doi.org\/10.1097\/md.0000000000026138.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1400_CR111","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2018;28(1):79\u201387. https:\/\/doi.org\/10.1089\/thy.2017.0285.","journal-title":"Thyroid"},{"key":"1400_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1738583","volume":"16","author":"K Liang","year":"2025","unstructured":"Liang K, Wang Z, Zhang Z, Liu G, Wang X, Cao H, et al. Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review. Front Immunol. 2025;16:1738583. https:\/\/doi.org\/10.3389\/fimmu.2025.1738583.","journal-title":"Front Immunol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01400-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:09:40Z","timestamp":1782115780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01400-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}